MASP-2 levels in RA patients, relatives and controls according to haplotype producing profiles.

<p>Data is shown with medians, differences were calculated with Kruskal-Wallis test A: Low MASP-2 producing haplotypes (<i>*2B2B-l/*1A</i>, <i>*2B2A-i/*2B2B-l</i>, <i>2B2B-l/2A1</i>, <i>*2B2A-i/*2A2-l</i>, <i>2B1-i/2A2-l</i>, <i>*2B1-i/*1C2-l</i>, <i>*1C2-l/*1C2-l</i>, <i>*2B2A-i/*1C2-l</i>, <i>*2B2B-l/*1C2-l</i>, <i>*2A2-l/*1C2-l</i>); B: Intermediary MASP-2 producing haplotypes (<i>*2B2A-i/*2B2A-i</i>, <i>*2B2A-i/*1A</i>, <i>*2B2A-i/*2B1-i</i>, <i>*2B1-i/*1A</i>, <i>*2B1-i/2A1</i>, <i>*2B1-i/*2B1-i</i>); C: High MASP-2 producing haplotypes (<i>*2B2A-i/*1B1-h</i>, <i>*2B2A-i/*1B2-h</i>, <i>*2B1-i/*1B1-h</i>, <i>*1B1-h/*1B1-h</i>, <i>*1A/*1B1-h</i>, <i>*2A1/1B1-h</i>, <i>*2A1/*2A1</i>, <i>*2B2A-i/*2A1</i>, <i>*2A1/*1A</i>, <i>*2B2A-i.1B1-h/1B1-h</i>).</p

Clinical and demographic data of RA patients.

a<p>: Total number of samples with available data for the extra-articular manifestation.</p

Differences between MASP-2 levels of patients, relatives with and without articular symptoms, and controls.

<p>Data is shown in medians and interquartile ranges, differences were calculated with Mann-Whitney tests (P<0.0001 between patients and controls, and patients and asymptomatic relatives; P = 0.0339 between symptomatic relatives and controls and P = 0.0143 between symptomatic and asymptomatic relatives). AS: articular symptom.</p

<i>MASP2</i> haplotypes nomenclature and frequencies (% ± SD).

a<p>: phylogenetic nomenclature according to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0090979#pone.0090979-Boldt2" target="_blank">[26]</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0090979#pone.0090979-Nebert1" target="_blank">[38]</a>, where “h”, “ï” and “l” refer to <i>MASP2</i> haplotypes associated with low (<200 ng/ml), intermediary (200–600 ng/ml) and high (≥600 ng/ml) MASP-2 levels (cut off adopted by <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0090979#pone.0090979-Boldt2" target="_blank">[26]</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0090979#pone.0090979-Probst1" target="_blank">[35]</a>),</p>b<p>: reference sequence NT_021937 (GenBank sequence); anti-CCP: anti-cyclic citrullinated peptide antibodies; n: number of chromosomes; SD: standard deviation. In bold: recombinant haplotype.</p

Reduced binary logistic regression models for rheumatoid arthritis.

<p>The original model included age, gender and ethnicity for all observations; smoking habit, anti-CCP and RF positivity for patients and relatives. Significance of the model is given in parentheses. MASP-2 levels were normalized as logarithms on base 10 (Log₁₀). anti-CCP: anti-cyclic citrullinated peptide antibodies; n: number of included observations; &: not independent; OR: odds ratio;</p>a<p>: with intermediary levels,</p>b<p>: with low MASP-2 levels.</p

Correlations between anti-CCP and patient’s age and age at disease onset.

<p>Anti-CCP correlated with the age of patients (A) and age at disease onset (C). Anti-CCP studied according to patient’s age (B) and age at disease onset (D).</p

Clinical and demographic features of the RA patients, relatives and healthy controls.

<p>Anti-CCP: anti-cyclic citrullinated peptide antibody, (^a): Total of samples with available data are 154; (^b): Total samples with available data are 74.</p><p>NS: Not significant; NA: not available; ND: not determined. Values expressed in medians and interquartiles range.</p

Distribution of MBL levels in different <i>MBL2</i> haplotypes and diplotypes.

<p><i>MBL2</i> diplotypes were reconstructed from promoter variant −221X/Y and variants in exon1 (Codon 52+54+57, A/O) and divided into high MBL producers (<i>YA/YA</i>), intermediate (<i>YA/YO</i>, <i>XA/XA</i> and <i>XA/YA</i>) and low MBL producers (<i>YO/YO</i>, <i>XA/YO</i>). Serum MBL levels were segregated according to different <i>MBL2</i> diplotypes in patients and relatives (A), and different <i>MBL2 </i>secretor haplotypes in RA patients (B) and relatives (C).</p

Distribution of MBL levels in different <i>MBL2</i> genotypes.

<p>Serum MBL levels according to different genotypes of studied <i>MBL2</i> variants in RA patients (A) and relatives (B).</p

Distribution of MBL levels in RA patients segregated by clinical parameters.

<p>Distribution of MBL levels according to presence of nodules (A), Secondary Sjögren’s syndrome (B), positivity for anti-CCP (C) and positivity for Rheumatoid factor (D).</p